Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters

Abstract

AimTo evaluate the efficacy and tolerability, any changes in lipid parameters including free fatty acids and effect on weight and blood pressure, of adding Rosiglitazone to patients with type 2 DM who are not adequately controlled on maintenance dose of Metformin. MethodsProspective study of 14 patients with type 2 DM who were maintained on Metformin alone (1.5–2.5g/day). Twelve patients met the inclusion criteria, and received 4mg of Rosiglitazone daily in addition to Metformin. Patients were followed for 24 weeks and seen for 6–7 visits. The dose of Rosiglitazone was increased after 8 weeks if FBG was still ⩾160mg/dl. Full biochemical evaluation was done and safety parameters were observed at base line, at intervals during the study and at the end of the study. All patients completed the study. T test was used for comparison. ResultsEight males and four females were studied. They had the following characteristics: Mean age was (52±6.9) years, weight was (78.2±10.1)kg BMI was (28±4)kg/m2, waist circumference was (97.5±6.5)cm, and duration of DM was (7.3±6) years. Four patients required an increase of Rosiglitazone dose to 8mg after 8 weeks.All patients showed improvement of HbA1c levels by the end of the study. When mean base line parameters were compared to those at the end of study: HbA1c level dropped from (8.9%±1.5) to (7.1%±1.1) (P: 0.00003) and FBG from (205±50.6) to (150±28)mg/dl (P: 0.002). Free Fatty Acids (FFA) dropped from (703±213) to (510±303.6) by 8 weeks and to (574±184.6) μeq/L by the end of the study, (P: 0.01 and 0.06, respectively). Improvement in HbA1c did not however correlate with the level of FFA drop. There was also significant increase in HDL level (1.15±0.14)–(1.27±0.2)mmol/L, (P: 0.02), and weight (78.2±10.1)–(80.1± 10.9)kg (P: 0.01). The changes in LDL (3.02±0.57)–(3.23±0.5)mmol/L, TG (2.16±1.1)–(2.2±1.33)mmol/L, waist circumference (97.5±6.5)–(99±8.1)cm, and BP (132.5±17)–(130.2±18.8)mm Hg (systolic), were not significant.When “Good Responders”, (HbA1c drop of >1.5%), (nine subjects) were compared to those with less than 1.5% drop (three subjects), there were no specific characteristics to define responders. ConclusionRosiglitazone, added to Metformin in type 2 DM patients, was effective and well tolerated. There was a significant decrease in FFA levels with treatment. The response to treatment, however could not be predicted from biochemical or clinical parameters. A larger study may be needed to define responder characteristics.